Focus: MapLight Therapeutics is a Burlington, MA-based biotech company developing optogenetics-based therapies for rare neuropsychiatric diseases. The company is in Series C+ funding stage with active Phase 2 programs targeting autism spectrum disorder, schizophrenia, and Alzheimer's-associated psychosis.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Strong fit for early-career researchers and clinical operations professionals seeking deep involvement in novel mechanism discovery; higher risk for those prioritizing financial stability or established commercial infrastructure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MapLight Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MapLight Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times
MapLight Therapeutics to Participate in Upcoming Investor Conference The Manila Times
Raymond James initiates coverage on MapLight Therapeutics with Strong Buy - scanx.trade
Raymond James initiates coverage on MapLight Therapeutics with Strong Buy scanx.trade
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT MarketBeat
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT MarketBeat
5AM Venture Management LLC Makes New Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
5AM Venture Management LLC Makes New Investment in Maplight Therapeutics, Inc. $MPLT MarketBeat
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo